P1405Optimal serum low-density lipoprotein cholesterol management after endovascular therapy for symptomatic peripheral artery disease

Endovascular Therapy ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Peripheral Artery ◽

Artery Disease ◽

Cholesterol Management

P1635Impact of serum low-density lipoprotein cholesterol level after endovascular therapy for symptomatic peripheral artery disease

European Heart Journal ◽

10.1093/eurheartj/ehy565.p1635 ◽

2018 ◽

Vol 39 (suppl_1) ◽

Author(s):

Y Tomoi ◽

K Yamaji ◽

Y Soga ◽

S Hiramori ◽

K Ando

Keyword(s):

Cholesterol Level ◽

Endovascular Therapy ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Peripheral Artery ◽

Artery Disease

Impact of different statins on low-density lipoprotein cholesterol levels in patients with peripheral artery disease

Atherosclerosis ◽

10.1016/j.atherosclerosis.2021.06.886 ◽

2021 ◽

Vol 331 ◽

pp. e288

Author(s):

K. Gebauer ◽

N. Malyar

Keyword(s):

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Peripheral Artery ◽

Cholesterol Levels ◽

Artery Disease

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Circulation ◽

10.1161/circulationaha.117.032235 ◽

2018 ◽

Vol 137 (4) ◽

pp. 338-350 ◽

Cited By ~ 253

Author(s):

Marc P. Bonaca ◽

Patrice Nault ◽

Robert P. Giugliano ◽

Anthony C. Keech ◽

Armando Lira Pineda ◽

...

Keyword(s):

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Peripheral Artery ◽

Cholesterol Lowering ◽

Artery Disease

The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease

Journal of Vascular Surgery ◽

10.1016/j.jvs.2020.08.129 ◽

2020 ◽

Author(s):

Domenico R. Nastasi ◽

Joseph V. Moxon ◽

Richard Norman ◽

Alexandra F. Trollope ◽

Sophie Rowbotham ◽

...

Keyword(s):

Cost Effectiveness ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Peripheral Artery ◽

Artery Disease ◽

The Cost

Faculty Opinions recommendation of Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732115059.793542827 ◽

2018 ◽

Author(s):

Wilbert Aronow

Keyword(s):

Outcomes Research ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Elevated Risk ◽

Low Density ◽

Peripheral Artery ◽

Artery Disease ◽

Should We Adjust Low-Density Lipoprotein Cholesterol Management to the Severity of Coronary Artery Disease?

JACC Cardiovascular Imaging ◽

10.1016/j.jcmg.2020.04.007 ◽

2020 ◽

Vol 13 (9) ◽

pp. 1973-1975

Author(s):

William S. Weintraub ◽

Armin Arbab-Zadeh

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Artery Disease ◽

Cholesterol Management

Letter by Calabrò et al Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)”

Circulation ◽

10.1161/circulationaha.117.033137 ◽

2018 ◽

Vol 138 (2) ◽

pp. 218-219

Author(s):

Paolo Calabrò ◽

Felice Gragnano ◽

Arturo Cesaro

Keyword(s):

Outcomes Research ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Elevated Risk ◽

Low Density ◽

Peripheral Artery ◽

Artery Disease ◽

Response by Bonaca and Sabatine to Letters Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)”

Circulation ◽

10.1161/circulationaha.118.034864 ◽

2018 ◽

Vol 138 (2) ◽

pp. 222-223 ◽

Cited By ~ 1

Author(s):

Marc P. Bonaca ◽

Marc S. Sabatine

Keyword(s):

Outcomes Research ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Elevated Risk ◽

Low Density ◽

Peripheral Artery ◽

Artery Disease ◽

Letter by Alkhalil Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)”

Circulation ◽

10.1161/circulationaha.117.033207 ◽

2018 ◽

Vol 138 (2) ◽

pp. 220-221

Author(s):

Mohammad Alkhalil

Keyword(s):

Outcomes Research ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Elevated Risk ◽

Low Density ◽

Peripheral Artery ◽

Artery Disease ◽

Target level achievement of low-density lipoprotein cholesterol in patients with peripheral artery disease: Improvement potential despite increased statin use

Atherosclerosis ◽

10.1016/j.atherosclerosis.2021.06.885 ◽

2021 ◽

Vol 331 ◽

pp. e288

Author(s):

K. Gebauer ◽

N. Malyar

Keyword(s):

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Target Level ◽

Peripheral Artery ◽

Improvement Potential ◽

Artery Disease ◽

Statin Use